SOUTH SAN FRANCISCO, Calif. & PALO ALTO, Calif.--(BUSINESS WIRE)--Trellis Bioscience LLC (Trellis) and Open Monoclonal Technology, Inc. (OMT) today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT’s OmniRat™ platform. Trellis will apply its CellSpot™ antibody screening technology to libraries of OmniRat-generated B cells to discover high affinity, ultra rare antibodies with precisely defined specificity. Trellis will advance and partner each program and share the deal economics with OMT depending on the stage of development.
